Treatment of Alzheimer's Disease with Apathy
Apathy is one of the most prevalent neuropsychiatric features encountered in Alzheimer's disease, present in roughly half of patients at onset. When apathy is a prominent part of the clinical picture, it calls for specific management considerations beyond the core cognitive symptoms.
Alzheimer's disease presenting with apathy — a neuropsychiatric syndrome characterised by diminished motivation, reduced goal-directed behaviour, and emotional blunting. Apathy is present at the onset of Alzheimer's disease in about half of patients, making it one of the most common behavioural complications alongside irritability, depression, agitation, and sleep disturbances.
A specific pharmacological intervention may be appropriate in selected cases — particularly when apathy is severe. Evidence supporting its use is limited, and the threshold for initiating therapy reflects that constraint. The complete clinical criteria, agent selection, and sequencing are set out in the full protocol.
References
DOI: 10.1016/S0140-6736(25)01329-7Apathy is present at the onset of Alzheimer's disease in about half of patients, irritability in one-third, and depression, agitation, and sleep disturbances in one-quarter.
There is some indication that both stimulants, such as methylphenidate, and cholinesterase inhibitors might improve apathy in people with Alzheimer's disease, whereas agomelatine, a melatonin receptor agonist and serotonin receptor blocker, might be useful for treating apathy in people with frontotemporal dementia.
However, the evidence for these treatments is mainly from case series, and pharmacological therapy should probably be reserved for severe cases of apathy.
View source ↗